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main contributors to this extra cost were pharmaceuticals (1,687€; 50.2%) and
in-patient care (903€; 26.9%). The proportion of patients with other co-morbidities
leading to full coverage was not significantly different in the RA group versus
control (39.4% versus 41.8% p0.134) although Hypertension (7.8% versus 6.7%
p0.44) was significantly more frequent. Differences for Ischemic Heart Disease
(3.0% versus 2.5%) and Depression (1.9% versus 1.4%) were positive but did not
reach statistical significance.CONCLUSIONS:The economic burden of RA in France
to the health care system is significant and apparently not associated to the pres-
ence of severe co-morbidity as identified in this database.
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OBJECTIVES: There are 6,000 hip fractures annually in Finland with a population of
5.4 million. These elderly patients (average 80y) almost always require surgery.
Among elderly, 14% are using warfarin, and the anticoagulation effect should be
reversed prior to surgery. The four approaches commonly used are: cessation of
warfarin therapy, administration of vitamin-K, Fresh Frozen Plasma (FFP) or Pro-
thrombin Complex Concentrate (PCC). These approaches have different onset
times and thus, the choice of the method used influences the delay before the
surgery can safely be performed. Delay of the operation increases the number of
preoperative hospital days, and is associated with increased mortality. PCC acts as
an antidote, and thus enables immediate operation. METHODS: There were 232
patients with acute hip fracture in Kuopio University Hospital (KUH) in 2009 with a
30 days mortality of 18 patients and delay of 16 operations. Patients in need for
warfarin reversal were estimated, as well as additional hospital days caused by the
possible delay of surgery. Medication, laboratory costs, and cost of hospitalization
due to the delay were estimated for a one year perspective. Mortality rate w/wo
delay was estimated. RESULTS: There were estimated to be 29 patients with acute
hip fracture requiring warfarin reversal in KUH annually. Among these patients,
the reversal of anticoagulation with FPP, vitamin K, or cessation of warfarin leads to
30, 30 and 116 additional hospital days per year compared to PCC. The total costs
were 22 700€, 10200 €, 156 900€ and 20 300€ with FFP, vitamin-K, cessation of war-
farin and PCC, respectively. Mortality rate was estimated to be 10.6% and 7.5%
w/wo delay, respectively. CONCLUSIONS: Delay of the acute surgical intervention
increases health care costs. The use of antidote (PCC) decreases this delay among
warfarin users, and may lead to cost savings and decrease in mortality.
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OBJECTIVES: Postoperative thrombosis is a common complication after major or-
thopaedic surgery. Standard prophylaxis is done with subcutaneous injections of
low molecular heparin. Oral anticoagulants became available for this indication in
the last years. It was the aim of this study to develop a modelling matrix consider-
ing all types of costs in order to allow for a cost-benefit-analysis comparing anti-
coagulants in the post-operative setting. METHODS: This study is a prospective,
comparing clinical observation study. 90 patients after total hip/knee replacement
were included. Quality of life (QOL) was measured by an specific score (PACT-Q®).
Also the compliance was analyzed (Morisky). Clinical/labdata as well as informa-
tion on occurrence and reason of readmittance to the hospital were collected. This
analysis evaluates the cost-benefit-ratio of the oral anticoagulant rivaroxaban
compared with subcutaneous low molecular weight heparin certoparin-sodium
from the German patients’ and society‘s perspective. RESULTS: For this study a
new method was developed. The result is a matrix, which calculates the corrected
total costs (Cc) by multiplication of direct costs (CD) with a factor FQOL represent-
ing QOL. FQOLis the difference between optimal and actual quality of life (in). By
this method, the effect of QOL and compliance on total costs and on the value of a
therapy becomes visible. By application of two anticoagulants it became apparent,
that the corrected costs for rivaroxaban where lower (22,1%) than its direct costs,
resulting in a sum advantage for the innovative drug, although direct costs were
higher (9,7%) for the oral drug.CONCLUSIONS:Medicaments enter the market with
mostly higher prices compared to the standard. The payers should evaluate, if the
more expensive pharmaceutical product saves costs during the therapeutical path-
way or if the result generates a higher quality of life for the patients which could
mean better compliance with less costs for following treatments.
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OBJECTIVES: Ankylosing spondylitis (AS) is an inflammatory disease of unknown
cause. The study evaluated the cost effectiveness of adalimumab vs. placebo, goli-
mumab vs. placebo, and adalimumab vs. golimumab in patients with active AS
from the Italian payer perspective. METHODS: A cohort Markov model was devel-
oped to estimate over a time horizon of 40 years costs and QALYs associated with
adalimumab or golimumab, when used according to existing treatment guidelines.
The analysis was based on data from two Phase III studies of adalimumab and
golimumab in active AS (combined ATLAS and Canadian trials, and GO-RAISE,
respectively). Using the trial information, patients were categorized into respond-
ers and non-responders at week 12. In the base case model, response was defined
using the ASAS 20 criterion. A univariate and probabilistic sensitivity analyses was
performed to assess the robustness of the results. RESULTS: In the base case ada-
limumab therapy estimate 1.29 more discounted QALYs per patient vs. conven-
tional therapy anda total net cost (adalimumab vs. placebo) of € 43,617 per patient
resulting in an ICER of € 33,704/QALY. The analysis performed between golimumab
vs placebo led to ICER of € 39,149 per QALY gained. Comparing adalimumab to
golimumab, adalimumab resulted in 0.12 additional QALYs and € 2,350 in savings
and is therefore considered dominant. These results were sensitive to whether the
proportion of responders were adjusted for age or non-response imputation be-
tween trials and the proportion of patients who weighed over 100 kg and would
therefore require a higher dose of golimumab to reach similar effectiveness. The
results further favored adalimumab when indirect costs were included.
CONCLUSIONS: From the Italian payer and societal (in sensitivity analysis) per-
spectives, treatment of AS with adalimumab is cost saving and more effective
compared to golimumab, and thus is dominant versus golimumab, when used
according to the general treatment guidelines.
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OBJECTIVES: ADACTA trial (Gabay C et al EULAR June 2012) showed that tocili-
zumab (TCZ) monotherapy was superior to adalimumab (ADA) monotherapy in
reducing signs and symptoms of adult rheumatoid arthritis (RA) patients who were
either intolerant to methotrexate (MTX) or for whom continued MTX treatment
was inappropriate. The aim of the current study was to develop a cost-effective-
ness analysis of TCZ vs. ADA in MTX-intolerant/contraindicated patients.
METHODS: Economic evaluation based on ADACTA study was conducted to esti-
mate the incremental cost-effectiveness ratio (ICER) of TCZ vs. ADA. Time horizon
was 24 weeks. Patient’s response in the model was measured through ACR re-
sponse (ACR20/ACR50/ACR70) and DAS28 remission. Results were presented as
incremental cost of TCZ vs. ADA per response. The analysis was conducted from
the perspective of the Spanish National Healthcare System, considering drug costs.
Unitary costs (€, 2012) were obtained from a Spanish database. Simple univariate
sensitivity analyses were performed. RESULTS: ACR20 response rates were
achieved in 65% and 49.4% in the TCZ and ADA group respectively (p0.01). ACR50
response rates were achieved in 47.2% and 27.8% in TCZ and ADA group (p0.01)
and ACR70 response rates in 32.5% and 17.9% in TCZ and ADA group (p0.01)
respectively. DAS28 Remission was achieved in 39.9% and 10.5% in TCZ and ADA
group (p0.0001). Treatment with TCZ provided better results in cost per response
than ADA over 24 weeks in terms of ACR response (ACR20 €8,105 and €11,553;
ACR50 €11,162 and €20,382; ACR70 €15,965 and €31,705) and DAS 28 remission
€13,509 and €54,352 respectively. TCZ was dominant over ADA in ACR response and
DAS28 remission. Sensitivity analysis confirmed the stability of the results.
CONCLUSIONS: The results of this analysis suggest that TCZ monotherapy repre-
sents an efficient and cost-effective strategy vs. ADA in Spain, for treating RA
patients who are MTX intolerant/contraindicated.
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OBJECTIVES: The introduction of new biologic treatments has therefore dramati-
cally changed the therapeutic management of PsAThe objective of this study was
to determine the cost-effectiveness of biologic drugs for patients with moderate to
severe psoriatic arthritis (PsA) in Italy. METHODS: ACR and PASI response rates
from 8 randomized controlled trials were considered as indicators for clinical effi-
cacy. Short-term efficacy was based on relative probabilities of achieving ACR20
and PASI75 response in a meta-analysis. Published evidence and assumptions
were used to predict long-term efficacy. Treatment benefits were determined by
the relationship between HAQ and PASI with the EuroQoL 5D. Costs included drug
acquisition, administration, monitoring and hospitalisation. ICERs were calculated
by ordering treatments by QALYs, and comparing each treatment sequentially. A
40 year time horizon was considered, looking at the Italian perspective. RESULTS:
After palliative care, Golimumab was estimated to produce the next most QALYs.
However, in comparison to Golimumab, Adalimumab was estimated to provide an
additional 0.074 QALYs at less cost and so is a dominating strategy. In comparison
to palliative care, Adalimumab had an ICER of € 15,970 per QALY. Etanercept was
estimated to give similar additional QALYs and costs to Adalimumab. Infliximab
was estimated to provide 0.057 QALYs more than Etanercept, but this came with €
6,938 additional cost, giving Infliximab an ICER of € 121,806 per QALY versus Etan-
ercept. A number of one-way sensitivity analyses were performed finding various
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parameters (e.g. rate of HAQ progression and baseline demographics) and assump-
tions (e.g. extent to which HAQ improvement diminishes on withdrawal from ther-
apy) are influential on the ICER. CONCLUSIONS: Our results indicate that Adali-
mumab, and also Etanercept, have the highest probability of being the most cost-
effective of the biologic strategies at typical values of WTP.
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OBJECTIVES: Although osteoporosis is well recognized as a risk factor for fractures
among postmenopausal women, there has been no appraisal of the economic im-
pact of anti-osteoporotic therapy in Korea. Cost-effectiveness and cost-utility anal-
yses of anti-osteoporotic therapy were performed from the Korea National Health
Insurer perspective METHODS: Markov cohort simulation was performed to com-
pare the impact of bisphosphonates therapy to placebo in terms of incremental
cost per fracture averted and incremental cost per quality-adjusted life year (QALY)
saved for a hypothetical cohort of 1,000 Korean elderly osteoporotic women.
Within each health intervention strategy, all individuals began the simulation in
the health state ‘healthy’ and moved among the 5 health states (healthy, healthy
post-vertebral fracture, healthy post-hip fracture, healthy post 2nd hip fracture, and death)
in yearly cycles until 99 years old or death. To obtain transition probability of having
fractures, age-specific incidence rate of fracture was derived from published literature.
The combined weighted mean efficacy of alendronate and risedronate , which are the
most widely used bisphosphonates in Korea, for reducing the risk of fracture was
calculated from efficacy measures drawn from a meta-analysis. Data regarding
utilities and costs of fractures were derived from published local sources.RESULTS:
In the base case, the estimated incremental cost-utility ratio (ICUR) was 35 million
Korean won (KRW) per quality-adjusted life-year (QALY) gained, and the estimated
incremental cost-effectiveness ratio was 15 million KRW per fracture averted. Ac-
cording to the sensitivity analysis results, the efficacy of bisphosphonates therapy
and the starting age of therapy had the biggest impact on the estimated ICUR.
CONCLUSIONS: Based on this analysis, bisphosphonates therapy is likely to be
cost-effective for the primary prevention of fracture among Korean elderly women
at a willingness-to-pay threshold of 40-60 million KRW (i.e., 2-3 times per-capita
gross domestic product) per QALY.
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OBJECTIVES: To evaluate the cost per ACR70 response rate of biologic disease-
modifying antirheumatic drugs (bDMARDs) in the treatment of patients with active
rheumatoid arthritis (RA) and inadequate response to traditional DMARDs
(DMARD-IR) from the perspective of the Portuguese public health service.
METHODS: A systematic literature review considering randomized, controlled,
double-blind, multicentric clinical trials that evaluated the efficacy of bDMARDs’ -
abatacept, adalimumab, etanercept, golimumab, infliximab and tocilizumab – in
combination with DMARDs in the treatment of patients with active RA and
DMARD-IR, was performed, and 22 clinical trials were identified. ACR70 response
rates in each trial were adjusted for a placebo reference rate, which incorporated
the placebo response rates observed in all the trials. Odds ratio between the pla-
cebo group and the placebo reference group was thus assumed to reflect the base-
line differences between each trial results and a global reference population. Meta-
analyses were then performed to obtain the adjusted ACR70 response rate for each
bDMARD. The analysis considered drug and administration costs, obtained from
Portuguese official sources, and a 6-month time horizon. RESULTS: The highest
adjusted ACR70 response rate was obtained with tocilizumab (31,3%) followed by
adalimumab (25%), golimumab (20,2%), infliximab (19,6%), etanercept (15,5%) and
abatacept (11,7%), which is in line with earlier published evidence. Treatment costs
were lower with infliximab (4.577€) followed by tocilizumab (5.366€), etanercept
(5.695€), golimumab (5.921€), adalimumab (6104€) and abatacept (7.764€). The low-
est mean treatment cost to achieve an ACR70 response was obtained with tocili-
zumab (17.143€) followed by infliximab (23.354€), adalimumab (24.414€), goli-
mumab (29.311€), etanercept (36.743€) and abatacept (66.356€). CONCLUSIONS:
Due to the higher predicted ACR70 response rate, using tocilizumab for the treat-
ment of adult RA DMARD-IR patients provides the lowest cost per 70% or higher
improvement in disease activity among bDMARDs.
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Venous thromboembolism (VTE) is a disease that includes both deep vein throm-
bosis (DVT) and pulmonary embolism (PE), representing a serious public health
concern due to its impact in morbidity and mortality, and higher costs. Without
any prophylaxis, the incidence of DVT in patients undergoing total knee replace-
ment surgery (TKRS) ranges 40-84%. OBJECTIVES: To assess the cost and effective-
ness of bemiparin and enoxaparin when used as prophylaxis for VTE in TKRS under
the perspective of the Mexican public health care system. METHODS: We con-
ducted an economic evaluation based in a decision tree. Competing interventions
were bemiparin 3.500 IU/d started 6 hours after surgery and enoxaparin 40 mg/d
started 12 hours before surgery, for 102 days. Time horizon covered prophylaxis
plus 6 weeks of follow-up after hospital discharge. Probabilities of VTE events
(proximal DVT and symptomatic PE) as well as complications (major/minor bleed-
ing and thrombocytopenia) were derived from a head-to-head randomized double-
blind clinical trial. Only direct medical costs, comprising the acquisition cost of
agents used as prophylaxis besides the medical attention of VTE events and com-
plications, were analyzed. Resource use was determined by a Delphi Panel and
published literature. Unit costs were gathered from The Mexican Social Security
Institute (IMSS). Diagnosis-related groups’ costs at IMSS were also included into the
analysis. All costs are expressed in 2011 Mexican pesos (MXN). The efficacy mea-
sure was the proportion of patients free of VTE events. RESULTS: Selected VTE
events were 70% lower with bemiparin than with enoxaparin (18 vs. 60 cases per
1000 patients). Bemiparin also provided savings of 3521 MXN (47.4%) per patient
when used instead of enoxaparin for prophylaxis of VTE in TKRS. Model was
robust. CONCLUSIONS: Bemiparin is a dominant (both less costly and more effec-
tive) intervention over enoxaparin for the prophylaxis for VTE in TKRS in the Mex-
ican public health care setting.
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OBJECTIVES: RA prevalence is 0.5% in Turkey. This rate, as those in other Medi-
terranean countries, is lower compared with other European countries,. Initial RA
treatment consists of using Disease Modifying Anti-Rheumatic Drugs (DMARDs).
Following inadequate response to DMARDs patients may switch to biologic treat-
ment options including tumour-necrosis factor (TNF) inhibitors. Tocilizumab is
approved by Turkish Ministry of Health for the treatment of active RA patients who
have responded inadequately to previous anti-TNF therapy. The study aimed to
assess tocilizumab’s cost-effectiveness for treatment of active RA patients with
inadequate response to previous anti-TNF treatment in Turkey. METHODS: Cost-
effectiveness analysis performed from payer’s perspective considered direct med-
ical costs. Markov model was used to compare two treatment sequences:1) tocili-
zumab, rituximab, abatacept, leflunomide, cyclosporin, palliative care, and 2)
rituximab, abatacept, leflunomide, cyclosporin, palliative care. Time horizon was
end of life. Patient characteristics were based on phase III study data (RADIATE).
Mixed treatment comparison was used to adjust ACR response rates for each of the
treatments in both sequences. Relationship between HAQ-DI scores and EuroQol
(EQ-5D) utilities was modeled by using patient data from trials. Resource use was
estimated based on expert opinion. Treatment costs (drug acquisition, administra-
tion, monitoring) were obtained from official lists published by Turkish Ministry of
Health and public payer. Costs and effects were not discounted. Results were tested
using deterministic and probabilistic sensitivity analyses. RESULTS: Treatment
sequence initiated with tocilizumab resulted in 0,528 life years gained and 1,873
QALYs more than alternative sequence at an additional cost of TRY63.788. ICER
was TRY34.052/QALY, which is below the threshold (TRY53.000/QALY based on
WHO recommendation). Sensitivity analyses confirmed that ICER was below the
threshold in 97% of the samples. CONCLUSIONS: Treatment initiated with tocili-
zumab in active RA patients with inadequate response to previous anti-TNF treat-
ment is cost-effective compared to alternative treatment sequence in Turkey.
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OBJECTIVES: To evaluate the cost-effectiveness of denosumab compared to alen-
dronate, zoledronic acid and no active osteoporosis treatment, for the treatment of
post-menopausal osteoporosis (PMO) in elderly women aged 75 years and older in
Sweden. METHODS: A previously developed Markov cohort model was updated
and used to estimate costs and effects, i.e. reductions in fracture occurrence, of
denosumab vs. comparators in that elderly population. The model was populated
with Swedish data on cost and fracture risks, and available clinical trial evidence
on treatment fracture risk reduction for hip, vertebral and other fractures in an
elderly population aged 75 years or older, where available. A life-time perspective
was applied and analysis were performed both with the assumption that all pa-
tients stay on therapy for all 5 years and that some patients drop out of treatment
over time (i.e. adjusting for imperfect treatment persistence). RESULTS: The base-
case analysis showed that denosumab was cost-saving and more effective (i.e.
dominant) versus all three comparators. The cost savings without adjustment for
imperfect treatment persistence amounted to €4,500, €4,800 and €500 per patient,
compared to no treatment, zoledronate and alendronate, respectively. Hip fracture
is the most common fracture type in the elderly population, and denosumab treat-
ment for 5 years avoided 140, 100 and 55 hip fractures per 1,000 treated patients,
compared to no treatment, zoledronate and alendronate, respectively. Univariate
and probabilistic sensitivity analyses showed that results were stable; denosumab
dominated all comparators if consequences of imperfect treatment persistence
were included or if comparator treatment costs were set to zero. CONCLUSIONS:
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